SPECTRUM PHARMA Forum: Community User: AdlerX8

Neues Kursziel HC Wainwright: 12$. 😜 https://www.benzinga.com/analyst-ratings/22/09/28833191/hc-wainwright-co-maintains-buy-rating-for-spectrum-pharmaceuticals-heres-what-you-need-to-know

Glaube wir reden nun vom Eisernen Kreuz💩

Das Bronzene Kreuz. Jeder trägt sein Kreuz.... Mann Mann. Die Ami 🐖

Goldenes Kreuz 👍...bin beeindruckt, was sagt Dir der heutige Verlauf?

Zwei drei Tage Tage konsolidieren, ca. 1,23 $ Können nach Chart nochmal kommen. Aber der nächste Termin ist schon bald. Wer weiß

Großer Run verpufft

⁉️

Hoffentlich wird der Handel kurzfristig ausgesetzt!🙃

sieht doch gut aus👍

Ab 10:00 wird es lustig!😁

Ich denke die Woche wird gut😉🚀

News am Samstag... 😳 https://www.stocktitan.net/news/SPPI/spectrum-pharmaceuticals-announces-data-from-poster-presentation-for-zozi8u8ipxg5.html

Ich wünsche Euch allen ein meeega entspanntes Wochenende! 🍀😘😁

The U.S. Food and Drug Administration (FDA) has approved S.pectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. ROLVEDON (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation The company has received an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. The regulatory submission was supported by data from ADVANCE and RECOVER, two Phase 3 clinical trials which evaluated the safety and efficacy of ROLVEDON in 643 early-stage breast cancer patients for the management of neutropenia due to myelosuppressive chemotherapy. In both studies, ROLVEDON demonstrated the pre-specified hypothesis of non-inferiority (NI) in mean duration of severe neutropenia (DSN) and a similar safety profile to pegfilgrastim. Tom Riga, President and Chief Executive Officer, commented: "ROLVEDON's approval marks S.pectrum's transformation to a commercial-stage company with the opportunity to compete in a $2 billion dollar market, and offers a unique value proposition. This approval is a significant milestone for our development team and collaboration with Hanmi Pharmaceutical.” The company expects to launch with product available in the fourth quarter of 2022.

Ich habe auch nur noch ein paar, lass die mal liegen, egal was Montag passiert.